Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.

Trial Profile

Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2012

At a glance

  • Drugs Capecitabine (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2012 Results published in Breast Cancer Research and Treatment.
    • 24 Feb 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top